78 results about "Single-chain variable fragment" patented technology

The present invention is directed to a monoclonal anti-human CS1 clone 7A8D5 antibody or a single-chain variable fragment (scFv), comprising VH having the amino acid of SEQ ID NO: 4 and VL having the amino acid of SEQ ID NO: 5. The present invention is also directed to a chimeric antigen receptor fusion protein comprising from N-terminus to C-terminus: (i) CS1 scFv of the present invention, (ii) a transmembrane domain, (iii) at least one co-stimulatory domains, and (iv) an activating domain.

The present invention is directed to a humanized BCMA single-chain variable fragment (scFv), comprising VH having the amino acid sequence of SEQ ID NO: 4 and VL having the amino acid sequence of SEQ ID NO: 5. The present invention is also directed to a BCMA chimeric antigen receptor fusion protein comprising from N-terminus to C-terminus: (i) a single-chain variable fragment (scFv) of the present invention, (ii) a transmembrane domain, (iii) at least one co-stimulatory domains, and (iv) an activating domain. This humanized BCMA-CAR-T cells have specific killing activity with secretion of cytokine IFN-gamma in CAR-T cells in vitro and in vivo.

The present disclosure provides conjugates comprising a targeting moiety, such as an antibody, Fab fragment or single chain variable fragment (ScFv), and a lipid nanoparticle (LNP) encapsulating a therapeutic agent (i.e., payload) wherein the targeting moiety, such as an antibody, Fab fragment or ScFv, is conjugated to the lipid nanoparticle via a linker, and wherein the linker comprises an enzyme recognition sequence and a click product formed by a click reaction between a first click handle on the targeting moiety such as an antibody, Fab fragment or ScFv and a second click handle on the LNP.

Modified single chain variable fragments (scFv) that specifically bind CD147 are provided. Also provided are chimeric antigen receptors (CARs) including the modified CD147 scFv, nucleic acids encoding the CARs, vectors including the nucleic acids encoding the CARs, and immune cells expressing the CARs. Methods of treating a subject with cancer including administering to the subject an immune cell expressing a disclosed CD147-CAR are also provided.

The present disclosure provides conjugates comprising a targeting moiety, such as an antibody, Fab fragment or single chain variable fragment (ScFv), and a lipid nanoparticle (LNP) encapsulating a therapeutic agent (i.e., payload) wherein the targeting moiety, such as an antibody, Fab fragment or ScFv, is conjugated to the lipid nanoparticle via a linker, and wherein the linker comprises an enzyme recognition sequence and a click product formed by a click reaction between a first click handle on the targeting moiety such as an antibody, Fab fragment or ScFv and a second click handle on the LNP.

The present invention is directed to a humanized BCMA single-chain variable fragment (scFv), comprising VH having the amino acid sequence of SEQ ID NO: 4 and VL having the amino acid sequence of SEQ ID NO: 5. The present invention is also directed to a BCMA chimeric antigen receptor fusion protein comprising from N-terminus to C-terminus: (i) a single-chain variable fragment (scFv) of the present invention, (ii) a transmembrane domain, (iii) at least one co-stimulatory domains, and (iv) an activating domain. A preferred co-stimulatory domain is CD28 or 41-BB. The humanized BCMA-CAR-T cells have specific killing activity with secretion of cytokine IFN-gamma in CAR-T cells in vitro and in vivo.

Antibodies can treat neurodegenerative disorders (NDs) caused by misfolded proteins. Still, the blood-brain-barrier (BBB) resists their entry, a barrier that can be reduced by scFv instead of whole antibody and conjugating it with transferrin protein to induce transcytosis. While the scFv binds variable heavy and light chains with a non-cleavable linker, a cleavable linker between the scFv and transferrin protein can reduce exocytosis, enhancing the activity of the scFv.

Inventors followed an untargeted approach by screening a single chain variable fragment (scFv) library via phage display against recombinant human full-length wild-type (wt)TDP-43. They identified four wtTDP-43-specific scFv, two of which were retained following cellular expression and colocalization with TDP-43 in vitro. In silico binding site prediction on TDP-43 suggested the pathologically-relevant C-terminal and RRM1 domains as potential targets. One scFv diminished the amount of the insoluble 35-kDa C-terminal fragment of TDP-43 when the wildtype protein was overexpressed. Another scFv inhibited NF-κB activation associated with TDP-43 overexpression. Both scFv seemed to reverse some metabolic alterations caused by TDP-43 overexpression. Their findings offer two scFv molecules that bind wtTDP-43, alter its aggregation, and modify cellular pathways associated with TDP-43 proteinopathies. Accordingly, the present invention relates to scFv intrabodies targeting TDP-43 and their uses in diagnosis and treatment methods.

The present invention relates to: an antibody targeting a mutation of KRAS as an intracellular oncoprotein; or a fusion protein in which a cancer cell-penetrating peptide is linked to a single-chain variable fragment of the antibody by a genetic expression method or a chemical bonding method; and a tumor therapeutic use thereof. The fusion protein thus produced has the benefit of maximizing an anti-tumor or anticancer effect of the antibody or the single-chain variable fragment of the antibody targeting an intracellular oncoprotein or an oncomutant protein by effectively invading tumor cells.

The present invention relates to a mutant protein of a single-chain variable fragment having improved stability and, more specifically, to a mutant protein of a single-chain variable fragment having excellent binding affinity to immune checkpoint molecules and superior in vivo stability, in which a heavy-chain variable region including CDRH1 of SEQ ID NO: 1, CDRH2 of SEQ ID NO: 2, and CDRH3 of SEQ ID NO: 3 and a light-chain variable region including CDRL1 of SEQ ID NO: 4, CDRL2 of SEQ ID NO: 5, and CDRL3 of SEQ ID NO: 6 are linked by a stability-enhancing linker of SEQ ID NO: 7.

The present disclosure provides compositions and uses for binding a chimeric antigen receptor (CAR) or an antibody or antigen-binding fragment to the Vβ region of a T cell receptor. It also provides a method for treating diseases such as cancer or an autoimmune disease using a Vβ region-targeting molecule. The present disclosure provides a chimeric antigen receptor (CAR) comprising: (i) an antigen-binding molecule that specifically binds to a TCR Vβ region; (ii) an extracellular domain; (iii) a transmembrane domain; (iv) a costimulatory domain; and (v) an activation domain, wherein the antigen-binding molecule is a single-chain variable fragment (scFv) comprising a variable heavy chain (VH) set forth in any one of SEQ ID NOs: 45 to 131 and 534 to 544 and / or a variable light chain (VL) set forth in any one of SEQ ID NOs: 132 to 227 and 545 to 558.

The application relates to a dual cytokine fusion protein composition, pharmaceutical composition, and / or formulation thereof comprising the alpha and beta multi-subunits cytokines, such as IL-12 or IL-27, fused to a single chain variable fragment scaffolding system and a second cytokine, where the second cytokine is linked in the hinge region of the scFv. The application also relates to methods of using the dual cytokine fusion protein composition for treating cancer, inflammatory diseases or disorders, and immune and immune mediated diseases or disorders.

In aspects, a chimeric cytokine receptor (CCR) is provided that comprises (i) a single chain variable fragment (scFv) which specifically binds to an antigen, one or more extracellular interleukin receptor domains, an interleukin receptor transmembrane domain, and an interleukin receptor intracellular domain; and (ii) a single chain variable fragment (scFv) which specifically binds to an antigen, one or more extracellular interleukin receptor common gamma chain (γc) domains, a γc transmembrane domain, and a γc intracellular domain.

The present invention belongs to the technical fields of biomedicine and molecular biology, and particularly relates to a single-chain fragment variable (scFv) targeting human platelet-derived growth factor receptor (PDGFR)-β and use thereof in chimeric antigen receptor (CAR)-T cell immunotherapy. In the present invention, a scFv sequence targeting a human-derived PDGFRβ antigen is first obtained by immunizing a mouse, and then a second-generation CAR is constructed based on this, and additionally a CAR-T cell is obtained via lentivirus infection. The CAR-T cell can effectively kill a PDGFRβ antigen-positive 293T cell. The present invention provides a brand-new idea for eliminating PDGFRβ-positive cells to treat chronic kidney diseases, chronic liver diseases, cardiovascular diseases and various tumor diseases including various organ fibrosis, and has extremely attractive further development value and application prospects.

The present disclosure relates to novel nucleic acids for immune cell adapters, comprising a ribonucleic acid of formula I: R1-SP-R2-R3-R4-R5 (I) wherein R1 is a 5'non-transcriptional region (UTR); sP encodes a signal peptide; r2 encodes a first single chain variable fragment (scFv) that binds to a first extracellular protein or a heavy chain variable region (VH only) that binds to a first extracellular protein; r3 encodes a second scFv that binds to a second extracellular protein; r4 encodes a half-life extender; r < 5 > is 3 'UTR wherein R < 1 > to R < 5 > are in the 5' to 3 'direction for use in the treatment of cancer, including but not limited to hematological cancers, including multiple myeloma.

Provided are tetravalent bispecific antibodies (T-BiAbs) that have a first binding moiety and a second binding moiety, wherein the first binding moiety is a single chain variable fragment (scFv) and the second, binding moiety-7 is a monoclonal antibody, and further wherein the variable light (Vi.) and variable heavy7 (VH) chains of the first binding moiety7 are directly linked as a. single chain to the second binding moiety at the N-terminus or the C-terminus of the light chain or the heavy chain sequence of the second binding moiety. In some embodiments, the first binding moiety binds to a CDS polypeptide and the second binding moiety-7 binds to a tumor-associated antigen. Also provided are T cells armed with the presently disclosed T-BiAbs and methods of using the same for treating tumor and / or cancers, treating diabetes, arming and isolating stem cells, and manufacturing medicaments for these purposes.

The present disclosure provides compositions and methods related to the purification and / or isolation of antibodies. In particular, the present disclosure provides novel peptide ligands capable of targeting the fragment antigen binding (Fab) domain and / or single-chain variable fragment (scFv) of antibodies to facilitate the isolation and / or purification of antibodies from processing fluid streams. The novel ligands disclosed herein are capable of universal and subtype-specific biorecognition.

The application discloses a chimeric antigen receptor targeting CA9 and application thereof, and belongs to the technical field of biological medicine. The chimeric antigen receptor targeting CA9 comprises a CD8 alpha leader signal peptide, an anti-CA9 single-chain variable fragment, a CD8 alpha hinge, a CD8 transmembrane domain and a CD3 zeta intracellular costimulatory signaling domain. The application adopts the anti-CA9 single-chain variable fragment as an antigen binding domain to construct a chimeric antigen receptor (CAR) molecule, and the macrophage expressing the anti-CA9 CAR can realize specific targeting and phagocytosis and killing of CA9 positive renal cancer cells, the constructed lipid nanoparticle delivery system can effectively carry a gene expression vector, so that the gene expression vector can realize effective target site delivery, and the constructed hydrogel-liposome combined drug delivery system has the performances of relieving toxic and side effects, controllable release and hemostasis.

Antibodies can treat neurodegenerative disorders (NDs) caused by misfolded proteins. Still, the blood-brain-barrier (BBB) resists their entry, a barrier that can be reduced by scFv instead of whole antibody and conjugating it with transferrin protein to induce transcytosis. While the scFv binds variable heavy and light chains with a non-cleavable linker, a cleavable linker between the scFv and transferrin protein can reduce exocytosis, enhancing the activity of the scFv.

The invention provides a fusion protein, a nucleic acid construct encoding the fusion protein and regulatory T-cells (Treg) expressing the fusion protein for use in the treatment of inflammatory bowel disease, wherein the fusion protein is a chimeric antigen receptor (CAR) having a single chain variable fragment (scFv) domain specific for being activated by the location of inflammatory bowel disease, especially binding to one of meprin 1α (MEP1A) and cadherin 17 (CDH17), a transmembrane domain and at least one intracellular signalling domain. The scFv domains specific for MEP1A or CDH17 have been found to selectively bind to intestine afflicted by inflammatory bowel disease and to activate suppressive activity in Treg expressing the CAR at the location of inflammatory bowel disease. Specifically, the invention provides a CAR for use in the treatment of an immune response, e.g. in the treatment of an autoimmune response, which is directed against MEP1A or directed against CDH17.

Provided are anti- DLL3 chimeric antigens receptors (CARs), DLL3 binding proteins, and uses of such CARs or DLL3 binding proteins in the treatment of DLL3 associated disorders (e.g., small cell lung carcinoma).SOLUTION: Provided is a chimeric antigen receptor (CAR) comprising a DLL3 binding domain, wherein the DLL3 binding domain comprises or is derived from a single domain antibody (sdAb) or a single chain variable fragment (scFv).SELECTED DRAWING: None

The invention discloses a CAR-T cell based on a secretion enhancement strategy as well as a preparation method and medical application thereof. The constructed asCAR-T cell contains a secretion-enhanced chimeric antigen receptor (asCAR for short) and small interfering nucleic acid of DDR1 protein. The asCAR sequentially comprises a single-chain variable fragment scFv, a hinge region, a transmembrane domain, a costimulatory factor, a signal transduction structural domain CD3 zeta and TNFRSF1B ICD from an extracellular structure to an intracellular structure, wherein the TNFRSF1B ICD is a TRAF2 binding structural domain in a TNFR2 cell; the small interfering nucleic acid of the DDR1 protein comprises shRNA-DDR1 (short hairpin ribonucleic acid) or miRNA-DDR1 (micro ribonucleic acid). After the antigen activates the asCAR-T cells, the ICD of the TNFRSF1B enhances the expression of the PD-1 through the NF-kappa B pathway and releases the extracellular vesicles loaded with the shRNA-DDR1 or the miRNA-DDR1. The extracellular vesicles released by the asCAR-T cells degrade PD-L1 on the surfaces of tumor cells and inhibit DDR1 expression, and the immune infiltration and anti-tumor effects of the asCAR-T cells are enhanced based on the positive feedback loop.

In aspects, a chimeric cytokine receptor (CCR) is provided that comprises (i) a single chain variable fragment (scFv) which specifically binds to an antigen, one or more extracellular interleukin receptor domains, an interleukin receptor transmembrane domain, and an interleukin receptor intracellular domain; and (ii) a single chain variable fragment (scFv) which specifically binds to an antigen, one or more extracellular interleukin receptor common gamma chain (γc) domains, a γc transmembrane domain, and a γc intracellular domain.

This document provides methods and materials for assessing a mammal having or suspected of having cancer and / or for treating a mammal having cancer. For example, molecules including one or more antigen-binding domains (e.g., a single-chain variable fragment (scFv)) that can bind to a modified peptide (e.g., a tumor antigen), as well as method for using such molecules, are provided.

Binding domains that bind the Whitlow linker and subsequences thereof are described. The binding domains can be used as research, diagnostic, and therapeutic tools in combination with Whitlow-containing molecules, such as single chain variable fragments (scFv) and chimeric antigen receptors (CAR).

Disclosed herein, in certain aspects, are materials and methods for molecules comprising improved single chain variable fragments.

Antibodies can treat neurodegenerative disorders (NDs) caused by misfolded proteins. Still, the blood-brain-barrier (BBB) resists their entry, a barrier that can be reduced by scFv instead of whole antibody and conjugating it with transferrin protein to induce transcytosis. While the scFv binds variable heavy and light chains with a non-cleavable linker, a cleavable linker between the scFv and transferrin protein can reduce exocytosis, enhancing the activity of the scFv.

Antibodies can treat neurodegenerative disorders (NDs) caused by misfolded proteins. Still, the blood-brain-barrier (BBB) resists their entry, a barrier that can be reduced by scFv instead of whole antibody and conjugating it with transferrin protein to induce transcytosis. While the scFv binds variable heavy and light chains with a non-cleavable linker, a cleavable linker between the scFv and transferrin protein can reduce exocytosis, enhancing the activity of the scFv.

Antibodies can treat neurodegenerative disorders (NDs) caused by misfolded proteins. Still, the blood-brain-barrier (BBB) resists their entry, a barrier that can be reduced by scFv instead of whole antibody and conjugating it with transferrin protein to induce transcytosis. While the scFv binds variable heavy and light chains with a non-cleavable linker, a cleavable linker between the scFv and transferrin protein can reduce exocytosis, enhancing the activity of the scFv.